AstraZeneca makes a big RNA play, teaming up with VaxEquity
pharmaphorum
SEPTEMBER 23, 2021
Development of the shot eventually fell behind mRNA rivals from BioNTech and Moderna, and Imperial eventually pivoted its efforts to development of possible boosters directed at emerging variants based on its self-assembling RNA (saRNA) platform. billion takeover of Translate Bio and $470 million acquisition of Tidal Therapeutics.
Let's personalize your content